全文获取类型
收费全文 | 28808篇 |
免费 | 2520篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 255篇 |
儿科学 | 928篇 |
妇产科学 | 627篇 |
基础医学 | 4035篇 |
口腔科学 | 409篇 |
临床医学 | 3542篇 |
内科学 | 5443篇 |
皮肤病学 | 426篇 |
神经病学 | 2610篇 |
特种医学 | 796篇 |
外国民族医学 | 3篇 |
外科学 | 3372篇 |
综合类 | 589篇 |
一般理论 | 36篇 |
预防医学 | 3245篇 |
眼科学 | 967篇 |
药学 | 2172篇 |
中国医学 | 33篇 |
肿瘤学 | 1895篇 |
出版年
2023年 | 166篇 |
2022年 | 210篇 |
2021年 | 535篇 |
2020年 | 409篇 |
2019年 | 625篇 |
2018年 | 665篇 |
2017年 | 506篇 |
2016年 | 573篇 |
2015年 | 650篇 |
2014年 | 904篇 |
2013年 | 1280篇 |
2012年 | 1871篇 |
2011年 | 1933篇 |
2010年 | 981篇 |
2009年 | 965篇 |
2008年 | 1579篇 |
2007年 | 1766篇 |
2006年 | 1653篇 |
2005年 | 1693篇 |
2004年 | 1620篇 |
2003年 | 1425篇 |
2002年 | 1329篇 |
2001年 | 509篇 |
2000年 | 509篇 |
1999年 | 535篇 |
1998年 | 375篇 |
1997年 | 274篇 |
1996年 | 278篇 |
1995年 | 241篇 |
1994年 | 213篇 |
1993年 | 197篇 |
1992年 | 324篇 |
1991年 | 323篇 |
1990年 | 306篇 |
1989年 | 297篇 |
1988年 | 276篇 |
1987年 | 249篇 |
1986年 | 282篇 |
1985年 | 241篇 |
1984年 | 217篇 |
1983年 | 162篇 |
1982年 | 166篇 |
1981年 | 129篇 |
1980年 | 129篇 |
1979年 | 197篇 |
1978年 | 150篇 |
1977年 | 114篇 |
1976年 | 101篇 |
1974年 | 118篇 |
1973年 | 137篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
4.
5.
6.
7.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献8.
9.
10.